Crossmark

Bioequivalence Evaluation of Three Pediatric Oral Formulations of Bilastine in Healthy Subjects: Results from a Randomized, Open Label, Crossover Study

Crossref DOI link: https://doi.org/10.1007/s13318-019-00596-2

Published Online: 2019-12-09

Published Print: 2020-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sádaba, Belén https://orcid.org/0000-0002-7742-3736
Azanza, Jose Ramón https://orcid.org/0000-0003-3190-622X
García-Bea, Aintzane

Labeaga, Luis

Campo, Cristina

Valiente, Román
Funding

Funding for this research was provided by:

FAES FARMA S.A. (unknown)
License Information

Text and Data Mining valid from 2019-12-09

Version of Record valid from 2019-12-09
More Information

Article History

First Online: 9 December 2019

Compliance with Ethical Standards

:

: This work was supported by Faes Farma S.A.

: AGB, LL, CC, RV are workers of Faes Farma S. A.

: All procedures in this study were in accordance with the 1964 Helsinki declaration (and its amendments). The Ethic Committee for Clinical Investigation of Navarra (Spain) approved the study protocol and the consent information form on September 12, 2014. All volunteers gave their consent to participate in the study.

Document is current

Any future updates will be listed below